Hubei Biocause Pharmaceutical Co., Ltd. operates in the Life insurance sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hubei Biocause Pharmaceutical Co., Ltd. with three other
insurance companies in Asia:
Bajaj Finserv Limited
sales of 305.99 billion Indian Rupees [US$4.28 billion]
of which 56%
Tong Yang Life Insurance Company Limited
of South Korea
(5.00 trillion Korean Won [US$4.19 billion]
Orange Life Insurance Ltd
based in South Korea
(5.02 trillion Korean Won [US$4.21 billion]
of which 100%
was Insurance & Related Activities).
Hubei Biocause Pharmaceutical Co., Ltd. reported sales of 30.47 billion Chinese Renmimbi (US$4.32 billion)
December of 2018.
decrease of 42.9%
versus 2017, when the company's sales were 53.41 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 23.9% decline
in Insurance, from 46.91 billion Chinese Renmimbi to 35.72 billion Chinese Renmimbi.
However, these declines were partially offset by the increase in sales of
Pharmaceuticals and Chemical (up 10.6% to 574.84 million Chinese Renmimbi)